Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets

被引:5
|
作者
Valipour, Mehdi [1 ]
Di Giacomo, Silvia [2 ]
Di Sotto, Antonella [2 ]
Irannejad, Hamid [3 ]
机构
[1] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran 1545913487, Iran
[2] Sapienza Univ Rome, Dept Physiol & Pharmacol V Erspamer, Ple Aldo Moro 5, I-00185 Rome, Italy
[3] Mazandaran Univ Med Sci, Fac Pharm, Dept Med Chem, Sari 4847116547, Iran
关键词
chalcone; SARS-CoV-2; 3CLpro; PLpro; site-specific inhibitor; host-based targets; MM/PB(GB)SA; PAPAIN-LIKE PROTEASE; SERIES; ACE2; RECEPTOR; POTENT;
D O I
10.3390/ijms24108789
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previous studies indicated that natural-based chalcones have significant inhibitory effects on the coronavirus enzymes 3CLpro and PLpro as well as modulation of some host-based antiviral targets (HBATs). In this study, a comprehensive computational and structural study was performed to investigate the affinity of our compound library consisting of 757 chalcone-based structures (CHA-1 to CHA-757) for inhibiting the 3CLpro and PLpro enzymes and against twelve selected host-based targets. Our results indicated that CHA-12 (VUF 4819) is the most potent and multi-target inhibitor in our chemical library over all viral and host-based targets. Correspondingly, CHA-384 and its congeners containing ureide moieties were found to be potent and selective 3CLpro inhibitors, and benzotriazole moiety in CHA-37 was found to be a main fragment for inhibiting the 3CLpro and PLpro. Surprisingly, our results indicate that the ureide and sulfonamide moieties are integral fragments for the optimum 3CLpro inhibition while occupying the S1 and S3 subsites, which is fully consistent with recent reports on the site-specific 3CLpro inhibitors. Finding the multi-target inhibitor CHA-12, previously reported as an LTD4 antagonist for the treatment of inflammatory pulmonary diseases, prompted us to suggest it as a concomitant agent for relieving respiratory symptoms and suppressing COVID-19 infection.
引用
收藏
页数:32
相关论文
共 35 条
  • [1] SARS-CoV-2 potential drugs, drug targets, and biomarkers: a viral-host interaction network-based analysis
    Asmaa Samy
    Mohamed A. Maher
    Nehal Adel Abdelsalam
    Eman Badr
    Scientific Reports, 12
  • [2] SARS-CoV-2 potential drugs, drug targets, and biomarkers: a viral-host interaction network-based analysis
    Samy, Asmaa
    Maher, Mohamed A.
    Abdelsalam, Nehal Adel
    Badr, Eman
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [3] Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design
    Shao, Hai Ping
    Wang, Tian Hua
    Zhai, Hong Lin
    Bi, Ke Xin
    Zhao, Bing Qiang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 371
  • [4] Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2
    Ahmad, Sajjad
    Waheed, Yasir
    Abro, Asma
    Abbasi, Sumra Wajid
    Ismail, Saba
    JOURNAL OF MOLECULAR MODELING, 2021, 27 (07)
  • [5] Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2
    Sajjad Ahmad
    Yasir Waheed
    Asma Abro
    Sumra Wajid Abbasi
    Saba Ismail
    Journal of Molecular Modeling, 2021, 27
  • [6] Structural Basis for Inhibition of the SARS-CoV-2 nsp16 by Substrate-Based Dual Site Inhibitors
    Kalnins, Gints
    Rudusa, Laura
    Bula, Anna L.
    Zelencova-Gopejenko, Diana
    Bobileva, Olga
    Sisovs, Mihails
    Tars, Kaspars
    Jirgensons, Aigars
    Jaudzems, Kristaps
    Bobrovs, Raitis
    CHEMMEDCHEM, 2024,
  • [7] Synthesis and In Silico Investigation of Isatin-Based Schiff Bases as Potential Inhibitors for Promising Targets against SARS-CoV-2
    Esam, Zohreh
    Akhavan, Malihe
    Lotfi, Maryam
    Bekhradnia, Ahmadreza
    CHEMISTRYSELECT, 2022, 7 (46):
  • [8] Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
    Xia, Shuai
    Chan, Jasper Fuk-Woo
    Wang, Lijue
    Jiao, Fanke
    Chik, Kenn Ka-Heng
    Chu, Hin
    Lan, Qiaoshuai
    Xu, Wei
    Wang, Qian
    Wang, Chao
    Yuen, Kwok-Yung
    Lu, Lu
    Jiang, Shibo
    CELL RESEARCH, 2022, 32 (04) : 404 - 406
  • [9] Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
    Shuai Xia
    Jasper Fuk-Woo Chan
    Lijue Wang
    Fanke Jiao
    Kenn Ka-Heng Chik
    Hin Chu
    Qiaoshuai Lan
    Wei Xu
    Qian Wang
    Chao Wang
    Kwok-Yung Yuen
    Lu Lu
    Shibo Jiang
    Cell Research, 2022, 32 : 404 - 406
  • [10] A Novel Cell- and Virus-Free SARS-CoV-2 Neutralizing Antibody ELISA Based on Site-Specific Labeling Technology
    Liu, Hongliang
    Liu, Tiantian
    Wang, Aiping
    Liang, Chao
    Zhu, Xifang
    Zhou, Jingming
    Chen, Yumei
    Liu, Yankai
    Qi, Yanhua
    Chen, Wenjing
    Zhang, Gaiping
    ANALYTICAL CHEMISTRY, 2024, 96 (46) : 18437 - 18444